Trial Profile
A retrospective study of safety of different anti-SARS-CoV-2 vaccines in systemic lupus erythematosus patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jun 2022
Price :
$35
*
At a glance
- Drugs AZD 1222 (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- 28 Jun 2022 New trial record
- 04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism